Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBIT Margin: 2022-2025

Historic EBIT Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to 160.77%.

  • InMed Pharmaceuticals' EBIT Margin fell 2535.00% to 162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 167.40%, marking a year-over-year decrease of 2108.00%. This contributed to the annual value of 160.77% for FY2025, which is 1750.00% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its EBIT Margin stood at 160.77% for FY2025, which was up 9.81% from 178.27% recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' EBIT Margin registered a high of 160.77% during FY2025, and its lowest value of 1,584.71% during FY2022.
  • For the 3-year period, InMed Pharmaceuticals' EBIT Margin averaged around 180.94%, with its median value being 178.27% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 138,094bps in 2023, then plummeted by 1,750bps in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' EBIT Margin (MRY) stood at 1,584.71% in 2022, then skyrocketed by 87bps to 203.77% in 2023, then increased by 13bps to 178.27% in 2024, then increased by 10bps to 160.77% in 2025.
  • Its EBIT Margin stands at 160.77% for FY2025, versus 178.27% for FY2024 and 203.77% for FY2023.